Ophthalmologist

FRANCIS PRICE

Dr. Francis Price

Many of our patients at Price Vision Group are unaware that the eye doctor performing their eye exam is one of the premier ophthalmologists and LASIK specialists in the world. Indianapolis patients of Dr. Francis Price Jr. know him as a caring and gifted doctor who prioritizes their eye health and vision. But the numerous patients and physicians who travel great distances to benefit from his expertise know him as one of the top corneal specialists in the field.

Education and Experience

Dr. Price was born and raised on the south side of Indianapolis. Prior to his distinguished career in ophthalmology, Dr. Price graduated Phi Beta Kappa from the University of Notre Dame. He earned his medical degree from Indiana University Medical School, where he also completed his residency in ophthalmology. He completed a prestigious fellowship in corneal and external eye disease at Tulane University. He earned board-certification in ophthalmology, and established Price Vision Group more than 30 years ago.

Dr. Price established a nationally ranked cornea fellowship program here in Indianapolis that provides exceptional training to the next generation of cornea surgeons. The first laser vision correction procedure in Indiana was performed at Price Vision Group. He has played a key role in advancing LASIK by working directly with the American Society of Cataract & Refractive Surgeons and the American Academy of Ophthalmology

Dr. Price, The Person

If he wasn’t an ophthalmologist, Dr. Price says that he might choose to be a guide or tracker as his occupation because he loves nature. He would enjoy helping others get the same enjoyment that he does from hiking and canoeing. He also enjoys growing things and gardening, so perhaps a farmer would be his other occupation.

During his free time, Dr. Price enjoys traveling. Dr. Price and his wife usually make it a family affair and include their children and grandchildren. They especially enjoy canoeing the Canadian boundary waters.



A word from our patients

WHAT OUR PATIENTS ARE SAYING ABOUT DR. PRICE


Miss America 2009 Katie Stam Irk
Katie signature

He is the corneal expert. You look at the statistics of his results and it just all fits together. Dr. Price changed my life.


KATIE STAM IRK, LASIK patient

Miss America 2009

View testimonial
Mark D Testimonial

I traveled all the way from California to have Dr. Price perform DMEK on both of my eyes due to Fuchs Dystrophy. He saved my career and I really appreciate Dr. Price’s great work.


MARK, DMEK patient

Orchestral Musician

Thanks to Dr. Price I can see everything around me and I feel better about coming to work. You have really made a big change in my life.


EDWARD, Cataract patient

Dentist



Read more about Dr. Price

OFFICIAL CV

  • Education
  • Honors and Awards
  • Publications
  • Research Studies

Fellowship
Cornea and External Disease
Tulane University

Residency
Department of Ophthalmology
Indiana University

Internship
Methodist Hospital

Doctorate of Medicine
Indiana University

Bachelor of Science
University of Notre Dame

  • Thomas C. Hasbrook Award – Bosma Visionary Opportunities Foundation (2017)
  • Life Achievement Honor Award – American Academy of Ophthalmology (2016)
  • Celebrating Catholic School Values Community Service Award (2015)
  • Asia Cornea Society Medalist (2014)
  • Barraquer Award for significant contributions in refractive surgery (2011)
  • Santa Caterina d’Oro da Siena award for excellence in medical research (2011)
  • Senior Achievement Award – American Academy of Ophthalmology (2009)
  • Health Care Heroes award, Indianapolis Business Journal (2008)
  • Albert D. Frost Memorial Lectureship, Ohio State University (2007)
  • Melvin Jones Fellow Award, Lions International Foundation (2007)
  • Silver Recognition Award, Indiana Academy of Ophthalmology (2006)
  • Vision Award, the Corneal Dystrophy Foundation (2006)
  • Person of Vision, Prevent Blindness Indiana (2006)
  • Indiana Hero, Indiana Pacers (2006)
  1. Miyajima T, Melangath G, Zhu S, et al. Loss of NQO1 generates genotoxic estrogen-DNA adducts in Fuchs Endothelial Corneal Dystrophy. Free Radic Biol Med. 2020 Epub ahead of print.
  2. Price MO, Pinkus D, Price FW Jr. Implantation of Presbyopia-Correcting Intraocular Lenses Staged After Descemet Membrane Endothelial Keratoplasty in Patients With Fuchs Dystrophy. 2020 Epub ahead of print.
  3. Price FW Jr, Feng MT. Impact of corneal guttata on cataract surgery results. J Cataract Refract Surg. 2019;45:1692.
  4. Malbran ES, Price FW Jr, Arganaraz Olivero JE, et al. Peripheral Reconstructive Lamellar Keratoplasty for Late Ectasia After Penetrating Keratoplasty in Keratoconus Eyes. 2019;38:1377-1381.
  5. Wentz SM, Price F, Harris A, Siesky B, Ciulla T. Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery.Exp Opin Pharmacother. 2019;20:1703-1709.
  6. Feng MT, Lewis DR, Monsef BS, Price FW Jr. Re: Campbell et al.: Evolution in the risk of cataract surgical complications among patients exposed to tamsulosin: a population-based study (Ophthalmology. 2019;126:490-496). Ophthalmology 2019;126:e69-e70.
  7. Miyai T, Vasanth S, Melangath G, Deshpande N, Kumar V, Benischke AS, Chen Y, Price MO, Price FWJr, Jurkunas UV. Activation of PINK1-Parkin-Mediated Mitophagy Degrades Mitochondrial Quality Control Proteins in Fuchs Endothelial Corneal Dystrophy. Am J Pathol. 2019;189:2061-2076.
  8. Price FW Jr, Price MO. Reply. Ophthalmology. 2019;126:e63.
  9. Saint-Jean A, Soper M, Den Beste K, Iverson S, Price MO, Price FW. Technique for Ensuring Type I Bubble Formation for Pre-Descemet Endothelial Keratoplasty Preparation. 2019;38:1336-1338.
  10. Price MO, Subramaniam K, Feng MT, Price FW Jr. Reply. Cornea. 2019;38:e26-e27.
  11. Subramaniam K, Price MO, Feng MT, Price FW Jr. Micropulse Transscleral Cyclophotocoagulation in Keratoplasty Eyes. 2019;38:542-545.
  12. Ianchulev T, Lane S, Masis M, Lass JH, Benetz BA, Menegay HJ, Price FW, Lin S. Corneal Endothelial Cell Density and Morphology After Phacoemulsification in Patients With Primary Open-Angle Glaucoma and Cataracts: 2-Year Results of a Randomized Multicenter Trial.Cornea 2019;38:325-331.
  13. Price FW Jr, Price MO. Will level I evidence trigger a tipping point in endothelial keratoplasty? 2019;126:27-28.
  14. Pasari A, Price MO, Feng MT, Price FW Jr. Cornea. 2019;38:e7.
  15. Tyson SL, Bafna S, Gira JP, et al. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg 2019;45:204-212.
  16. Pasari A, Price MO, Feng MT, Price FW Jr. Descemet membrane endothelial keratoplasty for failed penetrating keratoplasty: visual outcomes and graft survival. Cornea 2019;38:151-156.
  17. Lopes BT, Ramos IC, Salomao MQ, Guerra FP, Schallhorn SC, Schallhorn JM, Vinviguerra R, Vinciguerra P, Price FW Jr, Price MO, Reinstein DZ, Archer TJ, Belin MW, Machado AP, Ambrosio R Jr. Enhanced tomographic assessment to detect corneal ectasia based on artificial intelligence. Am J Ophthalmol 2018;195:223-232.
  18. Lautert J, Doshi D, Price FW Jr, Price MO. Corneal Epithelial Remodeling After Standard Epithelium-off Corneal Cross-linking in Keratoconic Eyes. J Refract Surg. 2018;34:408-412.
  19. Price MO, Lisek M, Kelley M, Feng MT, Price FW Jr. Endothelium-in Versus Endothelium-out Insertion With Descemet Membrane Endothelial Keratoplasty.  2018;37:1098-1101.
  20. Kocaba V, Katikireddy KR, Gipson I, Price MO, Price FW, Jurkunas UV. Association of the Gutta-Induced Microenvironment With Corneal Endothelial Cell Behavior and Demise in Fuchs Endothelial Corneal Dystrophy. JAMA Ophthalmol. 2018;136:886-892.
  21. Price DA, Kelley M, Price FW Jr, Price MO. Five-Year Graft Survival of Descemet Membrane Endothelial Keratoplasty (EK) versus Descemet Stripping EK and the Effect of Donor Sex Matching. 2018;125:1508-1514.
  22. Price MO, Lass JH, Price FW Jr. Clinical Factors for early and late endothelial cell loss after corneal transplantation. Current Ophthalmology Reports 2018 https://doi.org/10.1007/s40135-018-0179-y.
  23. Doshi H, Pabon S, Price MO, Feng MT, Price FW Jr. Overview of Systemic Candida Infections in Hospital Settings and Report of Candida After DMEK Successfully Treated With Antifungals and Partial Graft Excision.  2018;37:1071-1074.
  24. Price MO, Feng MT, Price FW Jr. Patient satisfaction with epithelium-off corneal crosslinking. J Cataract Refract Surg 2018;44:323-328.
  25. Crews JW, Price MO, Lautert J, Feng MT, Price FW Jr. Intraoperative hyphema in Descemet membrane endothelial keratoplasty alone or combined with phacoemulsification. J Cataract Refract Surg 2018;44:198-201.
  26. Bhadange Y, Lautert J, Li S, Lawando E, Kim ET, Soper MC, Price FW Jr., Price MO, Bonanno JA. Hypoxia and the Prolyl Hydroxylase Inhibitor FG-4592 Protect Corneal Endothelial Cells From Mechanical and Perioperative Surgical Stress. Cornea 2018;37:501-7.
  27. Katikireddy KR, White TL, Miyajima T, Vasanth S, Raoof D, Chen Y, Price MO, Price FW, Jurkunas UV. NQO1 downregulation potentiates menadione-induced endothelial-mesenchymal transition during rosette formation in Fuchs endothelial corneal dystrophy. Free Radic Biol Med. 2017;116:19-30.
  28. Price MO, Fairchild K, Feng MT, Price FW Jr. Prospective Randomized Trial of Corneal Cross-linking Riboflavin Dosing Frequencies for Treatment of Keratoconus and Corneal Ectasia. 2018;125:505-511.
  29. Price MO, Lisek M, Feng MT, Price FW Jr. Effect of Donor and Recipient Diabetes Status on Descemet Membrane Endothelial Keratoplasty Adherence and Survival. 2017;36:1184-1188.
  30. Lewis DR, Price MO, Feng MT, Price FW Jr. Recurrence of Granular Corneal Dystrophy Type 1 After Phototherapeutic Keratectomy, Lamellar Keratoplasty, and Penetrating Keratoplasty in a Single Population. 2017;36:1227-1232.
  31. Gonzalez A, Price MO, Feng MT, Lee C, Arbelaez JG, Price FW Jr. Immunologic Rejection Episodes After Deep Anterior Lamellar Keratoplasty: Incidence and Risk Factors. Cornea 2017;36:1076-1082.
  32. Price FW Jr. June consultation #6. J Cataract Refract Surg. 2017;43:858.
  33. Price FW Jr., Price MO. Combined Cataract/DSEK/DMEK: Changing Expectations. Asia Pac J Ophthalmol. 2017;6:388-392.
  34. Price MO, Gupta P, Lass J, Price FW Jr. EK (DLEK, DSEK, DMEK): New Frontier in Cornea Surgery. Annu Rev Vis Sci. 2017;3:69-90.
  35. Benischke A, Vasanth S, Miyai T, Katikireddy KR, White T, Chen Y, Halilovic A, Price M, Price F Jr., Liton PB, Jurkunas UV. Activation of mitophagy leads to decline in Mfn2 and loss of mitochondrial mass in Fuchs endothelial corneal dystrophy. Sci Rep. 2017;7:6656.
  36. Afshari NA, Igo RP Jr, Morris NJ, et al. Genome-wide association study identifies three novel loci in Fuchs endothelial corneal dystrophy. Nat Commun. 2017;8:14898.
  37. Zhang W, Li H, Ogando DG, Feng M, Price FW Jr, Tennessen JM, Bonanno JA. Glutaminolysis is essential for energy production and ion transport in human corneal endothelium. EBioMedicine. 2017;16:292-301.
  38. Fini ME, Schwartz SG, Gao X, Jeong S, Patel N, Itakura T, Price MO,Price FW Jr, Varma R, Stamer WD. Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res 2017;56:58-83.
  39. Gonzalez A, Price FW Jr, Price MO, Feng MT. Prevention and Management of Pupil Block After Descemet Membrane Endothelial Keratoplasty.Cornea 2016;35:1391-95.
  40. Katikireddy KR, Schmedt T, Price MO,Price FW, Jurkunas UV. Existence of Neural Crest-Derived Progenitor Cells in Normal and Fuchs Endothelial Dystrophy Corneal Endothelium. Am J Pathol 2016;186:2736-50.
  41. Price MO, Price DA, Bucci FA Jr, Durrie DS, Bond WI, Price FW Jr. Three-Year Longitudinal Survey Comparing Visual Satisfaction with LASIK and Contact Lenses. Ophthalmology 2016;123:1659-66.
  42. Price MO, Calhoun P, Kollman C, Price FW Jr, Lass JH. Descemet Stripping Endothelial Keratoplasty: Ten-Year Endothelial Cell Loss Compared with Penetrating Keratoplasty. Ophthalmology 2016;123:1421-7.
  43. Price DA, Price MO, Lopez A, Price FW Jr. Effect of Descemet Membrane Endothelial Keratoplasty on Color Vision in Patients With Fuchs Dystrophy. Cornea 2016;35:1045-8.
  44. Price MO, Price FW. Keratoplasty with glaucoma – survive or dive? US Ophthalmic Review 2016;9:23-4. http://www.touchophthalmology.com/articles/keratoplasty-glaucoma-survive-or-dive
  45. Price MO, Scanameo A, Feng MT, Price FW Jr. Descemet’s Membrane Endothelial Keratoplasty: Risk of Immunologic Rejection Episodes after Discontinuing Topical Corticosteroids. Ophthalmology 2016;123:1232-6
  46. Tanaoka A, Babar N, Hogan J, Kim M, Price MO, Price FW Jr, Trokel SL, Paik DC. An Evaluation of Lysyl Oxidase-Derived Cross-Linking in Keratoconus by Liquid Chromatography/Mass Spectrometry. Invest Ophthalmol Vis Sci. 2016;57:126-36.
  47. Price MO, Price FW Jr. Corneal cross-linking in the treatment of corneal ulcers. Curr Opin Ophthalmol 2016;27:250-5.
  48. Rosenfeld C, Price MO, Lai X, Witzmann FA, Price FW Jr. Distinctive and pervasive alterations in aqueous humor protein composition following different types of glaucoma surgery. Mol Vis 2015;25:911-8.
  49. Feng MT, Price FW Jr, McKee Y, Price MO. Memantine-Associated Corneal Endothelial Dysfunction. JAMA Ophthalmol 2015;133:1218-20.
  50. Price FW Jr, Feng MT, Price MO. Evolution of Endothelial Keratoplasty: Where Are We Headed? Cornea 2015;34:S41-7.
  51. Price MO, Feng MT, McKee Y, Price FW Jr. Repeat Descemet Membrane Endothelial Keratoplasty: Secondary Grafts with Early Intervention Are Comparable with Fellow-Eye Primary Grafts. Ophthalmology 2015;122:1639-44.
  52. Schoenberg ED, Price FW Jr, Miller J, McKee Y, Price MO. Refractive outcomes of Descemet membrane endothelial keratoplasty triple procedures (combined with cataract surgery). J Cataract Refract Surg 2015;41:1182-9.
  53. Arbelaez JG, Feng MT, Pena TJ, Price MO, Price FW Jr. A Year of Cornea in Review: 2013. Asia Pac J Ophthalmol 2015;4:40-50.
  54. Quek DT, Wong CW, Wong TT, Han SB, Htoon HM Ho CL, Tan DT, Price FW Jr, Price MO, Mehta JS. Graft Failure and Intraocular Pressure Control After Keratoplasty in Iridocorneal Endothelial Syndrome. Am J Ophthalmol 2015;160:422-9.
  55. Price MO, Feng MT, Scanameo A, Price FW Jr. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial. Cornea 2015;34:853-8.
  56. Epitropoulos AT, Fram NR, Masket S, Price FW Jr, Snyder ME, Stulting RD. Evaluation of a New Controlled Point Source LED Glare Tester for Disability Glare Detection in Participants With and Without Cataracts. J Refract Surg. 2015;31:196-201.
  57. Price MO, Knight OJ, Benetz BA, Debanne SM, Verdier DD, Rosenwasser GO, Rosenwasser M, Price FW Jr, Lass JH. Randomized, prospective, single-masked clinical trial of endothelial keratoplasty performance with 2 donor cornea 4°c storage solutions and associated chambers. Cornea 2015;34:253-6.
  58. Price FW Jr, Price MO. To intervene or not to intervene: that is the question. Ophthalmology 2015;122:6-7.
  59. Epstein RH, Mamalis N, Price FW 2nd, Price MO. Histopathologic analysis of successful endothelial keratoplasty following multiple failed keratoplasties. J Cataract Refract Surg 2015;41:460-3.
  60. Price MO, Price FW Jr. Evaluation of the toric implantable collamer lens for simultaneous treatment of myopia and astigmatism. Expert Rev Med Devices 2015;12:25-39.
  61. McKee Y, Price FW Jr, Feng MT, Price MO. Implementation of the posterior chamber intraocular lens intrascleral haptic fixation technique (glued intraocular lens) in a United States practice: Outcomes and insights. J Cataract Refract Surg 2014;40:2099-105.
  62. Lass JH, Riddlesworth TD, Gal RL, Kollman C, Benetz BA, Price FW Jr, Sugar A, Terry MA, Soper M, Beck RW. The effect of donor diabetes history on graft failure and endothelial cell density 10 years after penetrating keratoplasty. Ophthalmology 2015;122:448-56.
  63. Arbelaez JG, Price MO, Price FW Jr. Long-term follow-up and complications of stripping descemet membrane without placement of graft in eyes with Fuchs endothelial dystrophy. Cornea 2014;33:1295-9.
  64. Price MO, Price FW Jr, Kruse FE, Bachmann BO, Tourtas T. Randomized comparison of topical prednisolone acetate 1% versus fluorometholone 0.1% in the first year after descemet membrane endothelial keratoplasty. Cornea 2014;33:880-6.
  65. Feng MT, Price MO, Miller JM, Price FW Jr. Air reinjection and endothelial cell density in Descemet membrane endothelial keratoplasty: five-year follow-up. J Cataract Refract Surg 2014;40:1116-21.
  66. Price FW Jr, Patterson LE, Gorovoy MS. Re: Du et al: Incidence of Endophthalmitis after corneal transplant or cataract surgery in a Medicare population (Ophthalmology 2014;121:290-8). Ophthalmology 2014 Jun 3.
  67. Schoenberg ED, Price FW Jr. Modification of Siepser sliding suture technique for iris repair and endothelial keratoplasty. J Cataract Refract Surg 2014;40:705-8.
  68. Mitry D, Bhogal M, Patel AK, Lee BS, Chai SM, Price MO, Price FW Jr, Jun AS, Aldave AJ, Mehta JS, Busin M, Allan BD. Descemet Stripping Automated Endothelial Keratoplasty After Failed Penetrating Keratoplasty: Survival, Rejection Risk, and Visual Outcome. JAMA Ophthalmol 2014;132:742-9.
  69. Chaurasia S, Price MO, McKee Y, Price FW Jr. Descemet Membrane Endothelial Keratoplasty Combined With Epithelial Debridement and Mitomycin-C Application for Fuchs Dystrophy With Preoperative Subepithelial Fibrosis or Anterior Basement Membrane Dystrophy. Cornea 2014;33:335-9.
  70. Tenkman LR, Price FW, Price MO. Descemet Membrane Endothelial Keratoplasty Donor Preparation: Navigating Challenges and Improving Efficiency. Cornea 2014;33:319-325.
  71. Burkhart ZN, Feng MT, Price FW Jr. Price MO. One-year outcomes in eyes remaining phakic after Descemet membrane endothelial keratoplasty. J Cataract Refract Surg 2014;40:430-4.
  72. Chaurasia S, Price FW Jr, Gunderson L, Price MO. Descemet’s Membrane Endothelial Keratoplasty: Clinical Results of Single Versus Triple Procedures (Combined with Cataract Surgery). Ophthalmology 2014;121:454-8.
  73. Price FW Jr, Price MO. Evolution of endothelial keratoplasty. Cornea 2013;32:S28-32.
  74. Lass JH, Benetz BA, Gal RL, Kollman C, Raghinaru D, Dontchev M, Mannis MJ, Holland EJ, Chow C, McCoy K, Price FW Jr, Sugar A, Verdier DD, Beck RW. Donor age and factors related to endothelial cell loss 10 years after penetrating keratoplasty: specular microscopy ancillary study. 2013;120:2428-35.
  75. Cheng CY, Schache M, Ikram MK, et al. Nine loci for ocular axial length identified through genome-wide association studies, including shared loci with refractive error. Am J Hum Genet 2013;93:264-77
  76. Feng MT, Burkhart ZN, McKee Y, Price FW Jr. A Technique to Rescue Keratoprosthesis Melts. 2013; 32:1407-1411
  77. Zhang X, Igo RP Jr, Fondran J, et al. Association of smoking and other risk factors with Fuchs’ endothelial corneal dystrophy severity and corneal thickness. Invest Ophthalmol Vis Sci 2013;54:5829-35
  78. McKee Y, Price MO, Gunderson L, Price FW Jr. Rapid sequential endothelial keratoplasty with and without combined cataract extraction. J Cataract Refract Surg 2013;39:1372-6
  79. Price MO, Price FW. Descemet’s membrane endothelial keratoplasty surgery: update on the evidence and hurdles to acceptance. Curr Opin Ophthalmol 2013;24:329-35.
  80. Feng MT, Burkhart ZN, Price FW Jr, Price MO. Effect of Donor Preparation-to-Use Times on Descemet Membrane Endothelial Keratoplasty Outcomes. Cornea 2013;32:1080-2.
  81. Feng MD, Price MO, Price FW. Update on Descemet membrane endothelial keratoplasty (DMEK). Int Ophthalmol Clin 2013;53:31-45.
  82. Burkhart ZN, Feng MD, Price MO, Price, FW. Handheld Slit Beam Techniques to Facilitate DMEK and DALK. Cornea 2013;32:722-4.
  83. Verhoeven VJ, Hysi PG, Wojciechowski R, et al. Genome-wide meta-analyses of multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. Nat Genet 2013;45:314-8
  84. Price MO, Gorovoy M, Price FW, Benetz BA, Menegay HJ, Lass JH. Descemet’s Stripping Automated Endothelial Keratoplasty: Three-Year Graft and Endothelial Cell Survival Compared with Penetrating Keratoplasty. Ophthalmology 2013:120:246-51.
  85. Price MO, Tenkman LR, Schrier A, Fairchild KM, Trokel SL, Price FW. Photoactivated Riboflavin Treatment of Infectious Keratitis Using Collagen Cross-linking Technology. J Refract Surg 2012;28:706-13.
  86. Jivrajka R, Schultz KL, Price MO, Price FW, Wilensky JT, Edward DP, Vajaranant TS. Ocular Pulse Amplitude in Patients With Descemet Stripping Endothelial Keratoplasty. J Glaucoma 2014 Mar;23(3):142-4
  87. Price MO, Fairchild KM, Price FW. Comparison of Manual and Automated Endothelial Cell Density Analysis in Normal Eyes and DSEK Eyes. Cornea 2013;32:567-73.
  88. Anshu A, Price MO, Price FW. Descemet Membrane Endothelial Keratoplasty and Hybrid Techniques for Managing Failed Penetrating Grafts. Cornea 2013;32:1-4.
  89. Anshu A, Price MO, Price FW. Descemet Stripping Automated Endothelial Keratoplasty for Fuchs Endothelial Dystrophy-Influence of Graft Diameter on Endothelial Cell Loss. Cornea 2013;32:5-8.
  90. Anshu A, Planchard B, Price MO, Pereira CDR, Price FW. A Cause of Reticular Interface Haze and its Management After Descemet Stripping Endothelial Keratoplasty. Cornea 2012;31:1365-8.
  91. Anshu A, Price MO, Price FW. Descemet’s Stripping Endothelial Keratoplasty: Long-term Graft Survival and Risk Factors for Failure in Eyes with Preexisting Glaucoma. Ophthalmology 2012:119:1982-7.
  92. Tenkman L, Price MO, Price FW. Keratoconus onset after age 50. J Refract Surg 2012; 28:436-8.
  93. Anshu A, Price MO, Tan DTH, Price FW. Endothelial keratoplasty: a revolution in evolution

Survey of Ophthalmology 2012;57:236-52.

  1. Stulting, RD, Sugar A, Beck R, Belin M, Dontchev M, Feder RS, Gal RL, Holland EJ, Kollman C, Mannis MJ, Price F, Stark W, Verdier DD; for the Cornea Donor Study Investigator Group. Effect of Donor and Recipient Factors on Corneal Graft Rejection. Cornea 2012;31:1141-47.
  2. Kopplin LJ, Przepyszny K, Schmotzer B, et al. Relationship of Fuchs endothelial corneal dystrophy severity to central corneal thickness. Arch Ophthalmol 2012:130:433-9.
  3. Anshu A, Price MO, Price FW. Risk of Corneal Transplant Rejection Significantly Reduced with Descemet’s Membrane Endothelial Keratoplasty. Ophthalmology 2012;119:536-40.
  4. Afshari NA, Gorovoy MS, Yoo SH, Kim T, Carlson AN, Rosenwasser GO, Griffin NB, McCuen BW 2nd, Toth CA, Price FW Jr, Price M, Fernandez MM. Dislocation of the Donor Graft to the Posterior Segment in Descemet Stripping Automated Endothelial Keratoplasty. Am J Ophthalmol. 2011 Nov 19.
  5. Louttit MD, Kopplin LJ, Igo RP Jr, Fondran JR, Tagliaferri A, Bardenstein D, Aldave AJ, Croasdale CR, Price MO, Rosenwasser GO, Lass JH, Iyengar SK; FECD Genetics Multi-Center Study Group. A multicenter study to map genes for Fuchs endothelial corneal dystrophy: baseline characteristics and heritability. Cornea 2012;31:26-35.
  6. Guerra FP, Anshu A, Price MO, Giebel AW, Price FW. Descemet’s Membrane Endothelial Keratoplasty Prospective Study of 1-Year Visual Outcomes, Graft Survival, and Endothelial Cell Loss. Ophthalmology 2011;118:2368-73.
  7. Guerra FP, Anshu A, Price MO, Price FW. Endothelial keratoplasty: fellow eyes comparison of descemet stripping automated endothelial keratoplasty and descemet membrane endothelial keratoplasty. Cornea 2011;30:1382-6.
  8. Anshu A, Price MO, Price FW. Descemet’s Stripping Endothelial Keratoplasty Under Failed Penetrating Keratoplasty: Visual Rehabilitation and Graft Survival Rate. Ophthalmology 2011; 118:2155-60.
  9. Anshu A, Price MO, Richardson MR, Segu ZM, Lai X, Yoder MC, Price FW. Alterations in the aqueous humor proteome in patients with a glaucoma shunt device. Molecular Vision 2011;17:1891-1900. http://www.molvis.org/molvis/v17/a206
  10. Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, Gow JA, Klier SM, McNamara TR; Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. Curr Med Res Opin. 2011;27:1693-703.
  11. Cursiefen C, Colin J, Dana R, Diaz-Llopis M, Faraj LA, Garcia-Delpech S, Geerling G, Price FW, Remeijer L, Rouse BT, Seitz B, Udaondo P, Meller D, Dua H. Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br J Ophthalmol 2012;96:3-9.
  12. Price FW, Price MO, Arundhati A. Descemet stripping automated endothelial keratoplasty under failed penetrating keratoplasty: how to avoid complications. Am J Ophthalmol 2011;151:187-8.
  13. Olson R, Donnenfeld D, Bucci FA, Price FW, et al. Methicillin resistance of Staphylococcus species among health care and nonhealth care workers undergoing cataract surgery. Clin Ophthalmol 2010;4:1505-1514.
  14. Da Reitz Pereira C, Guerra FP, Price FW Jr, Price MO. Descemet’s membrane automated endothelial keratoplasty (DMAEK): visual outcomes and visual quality. Br J Ophthalmol 2011;95:951-4.
  15. Richardson MR, Segu ZM, Price MO, Lai X, Witzmann FA, Mechref Y, Yoder MC, Price FW. Alterations in the aqueous humor proteome in patients with Fuchs endothelial corneal dystrophy. Molecular Vision 2010; 16:2376-2383 http://www.molvis.org/molvis/v16/a255
  16. McCauley MB, Price MO, Fairchild KM, Price DA, Price FW. Prospective study of visual outcomes and endothelial survival with Descemet membrane automated endothelial keratoplasty. Cornea 2011;30:315-9.
  17. Price MO, Fairchild KM, Price DA, Price FW. Descemet’s stripping endothelial keratoplasty five-year graft survival and endothelial cell loss. Ophthalmology 2011; 118:725-9.
  18. Guerra FP, Price MO, Price FW. Is central pachymetry asymmetry between eyes an independent risk factor for ectasia after LASIK? J Cataract Refract Surg 2010;11:2016-7.
  19. Letko E, Price DA, Lindoso EM, Price MO, Price FW. Secondary graft failure and repeat endothelial keratoplasty after Descemet’s stripping automated endothelial keratoplasty. Ophthalmol 2011;118:310-4.
  20. Hayes DD, Shih CY, Shamie N, Terry MA, Price FW Jr, Price MO, Ritterband DC, Hannush SB, Gorovoy MS, Weisenthal RW, Ritch R, Liebmann JM, Udell IJ. Spontaneous reattachment of Descemet stripping automated endothelial keratoplasty lenticles: a case series of 12 patients. Am J Ophthalmol 2010;150:790-7.
  21. Price MO, Price FW. Deep anterior lamellar keratoplasty: coming of age. Br J Ophthalmol 2010;94:1275-6
  22. Price MO, Price FW. Descemet membrane endothelial keratoplasty. Int Ophthalmol Clin 2010;50:137-47.
  23. Price FW Jr, Price MO, Guerra F. Is excimer laser corneal surgery appropriate after resolution of corneal edema in fuchs dystrophy by descemet membrane endothelial keratoplasty? J Refract Surg 2011;27:299-302.
  24. Price MO, Price DA, Fairchild KM, Price FW. Rate and risk factors for cataract formation and extraction after Descemet stripping endothelial keratoplasty. Br J Ophthalmol 2010;94:1468-71
  25. Price MO, Price FW. Endothelial keratoplasty – a review. Clin Experiment Opthalmol 2010;38:128–140.
  26. Kwon RO, Price MO, Price FW, Ambrosio R, Belin MW. Pentacam characterization of corneas with Fuchs dystrophy treated with Descemet membrane endothelial keratoplasty. J Refract Surg 2010;26:972-9.
  27. Lass JH, Sugar A, Benetz BA, et al. Endothelial cell density to predict endothelial graft failure after penetrating keratoplasty. Arch Ophthalmol 2010;128:63-9.
  28. Price MO, Bidros M, Gorovoy M, Price FW, Benetz BA, Menegay HJ, Debanne SM, Lass JH. Effect of incision width on graft survival and endothelial cell loss after Descemet stripping automated endothelial keratoplasty. Cornea. 2010;29:523-7.
  29. Price MO, Gorovoy M, Benetz BA, Price FW, Menegay HJ, Debanne SM, Lass JH. Descemet’s stripping automated endothelial keratoplasty outcomes compared with penetrating keratoplasty from the Cornea Donor Study. Ophthalmology 2010;117:438-44.
  30. Price FW, Price MO. Spontaneous corneal clearance despite graft detachment after descemet membrane endothelial keratoplasty. Am J Ophthalmol 2010;149:173-4.
  31. Richardson MR, Price MO, Price FW, Pardo JC, Grandin JC, Yoder Proteomic analysis of human aqueous humor using multidimensional protein identification technology. Molecular Vision 2009;15:2740-50.
  32. Price MO, Giebel AW, Fairchild KM, Price FW. Descemet’s membrane endothelial keratoplasty: prospective multicenter study of visual and refractive outcomes and endothelial survival. Ophthalmology 2009;116:2361–2368.
  33. Letko E, Price MO, Price FW. Influence of original flap creation method on incidence of epithelial ingrowth after LASIK retreatment. J Refract Surg. 2009;25:1039-41.
  34. Sugar J, Montoya M, Dontchev M, Tanner JP, Beck RW, Gal RL, Gallagher S, Gaster R, Heck E, Holland EJ, Kollman C, Malling J, Mannis MJ, Woody J for the Cornea Donor Study Investigator Group.  Donor risk factors for graft failure in the Cornea Donor Study. Cornea 2009; 28: 981-985.
  35. McCauley MB, Price FW, Price MO. Descemet membrane automated endothelial keratoplasty: hybrid technique combining DSAEK stability with DMEK visual results. J Cataract Refract Surg 2009;35:1659-64.
  36. Vajaranant TS, Price MO, Price FW, Gao W, Wilensky JT, Edward DP. Visual acuity and intraocular pressure after Descemet’s stripping endothelial keratoplasty in eyes with and without preexisting glaucoma. Ophthalmology 2009;116:1644-50.
  37. Price FW, Price DA, Ngakeng V, Price MO. Survey of steroid usage patterns during and after low-risk penetrating keratoplasty. Cornea 2009;28:865-70.
  38. Sugar A, Tanner JP, Dontchev M, Tennant B, Schultze RL, Dunn SP, Lindquist TD, Gal RL, Beck RW, Kollman C, Mannis M, Holland E, for the Cornea Donor Study Investigator Group.  Recipient risk factors for graft failure in the Cornea Donor Study. Ophthalmology 2009; 116: 1023-1028.
  39. Price FW, Price MO, Grandin JC, Kwon R. Deep anterior lamellar keratoplasty with femtosecond-laser zigzag incisions. Journal of Cataract and Refractive Surgery 2009;35:804-808.
  40. Price FW, Price MO. Does endothelial cell survival differ between DSEK and standard PK? Ophthalmology 2009;116:367-8.
  41. Price MO, Jordan CS, Moore G, Price FW. Graft rejection episodes after Descemet stripping with endothelial keratoplasty: part two: the statistical analysis of probability and risk factors. Br J Ophthalmology 2009;93:391-5.
  42. Jordan CS, Price MO, Trespalacios R, Price FW. Graft rejection episodes after Descemet stripping with endothelial keratoplasty: part one: clinical signs and symptoms. Br J Ophthalmol 2009;93:387-90.
  43. Price FW, Price MO, Jordan CS. Safety of incomplete incision patterns in femtosecond laser-assisted penetrating keratoplasty. Journal of Cataract and Refractive Surgery 2008; 34:2099-2013.
  44. Ngakeng V, Hauck MJ, Price MO, Price FW. AlphaCor keratoprosthesis: a novel approach to minimize the risks of long-term postoperative complications. Cornea 2008;27:905-910.
  45. Price MO, Price FW, Stoeger C, Soper M, Bavuso T, Locke G. Central thickness variation in precut DSAEK donor grafts. J Cataract and Refract Surg 2008;34:1423-4.
  46. Price MO, Baig KM, Brubaker JW, Price FW, Rando Randomized, prospective comparison of precut vs surgeon-dissected grafts for descemet stripping automated endothelial keratoplasty. Am J Ophthalmol 2008;146:36-41.
  47. Price FW. Precut Tissue for Descemet Stripping Automated Endothelial Keratoplasty. Cornea 2008; 27: 630-1.
  48. Cornea Donor Study Investigator Group. Donor age and corneal endothelial cell loss 5 years after successful corneal transplantation. Specular microscopy ancillary study results. 2008 Apr;115(4):627-632.e8.
  49. Cornea Donor Study Investigator Group. The effect of donor age on corneal transplantation outcome results of the cornea donor study. 2008 Apr;115(4):620-626.e6.
  50. Vajaranant TS, Price MO, Price FW, Wilensky JT, Edward DP. Intraocular pressure measurements following Descemet stripping endothelial keratoplasty. Am J Ophthalmol 2008;145:780-6.
  51. Price FW, Price MO. Is it worthwhile to combine penetrating keratoplasty with glaucoma drainage implants? Cornea 2008; 27: 261-2.
  52. Price FW, Price, MO. Adult keratoplasty: has the prognosis improved in the last 25 years? Ophthalmology International, 2008; 28:141-146.
  53. Price FW, Price MO. Femtosecond laser shaped penetrating keratoplasty: one-year results utilizing a top-hat configuration. Am J Ophthalmol 2008;145:210-214.
  54. Price MO, Price FW. Endothelial cell loss after descemet stripping with endothelial keratoplasty influencing factors and 2-year trend. Ophthalmology 2008;115:857-865.
  55. Hainline BC, Price MO, Price FW, Choi DM. Central Flap Necrosis after LASIK. (reply) J Refract Surg 2007;23:741-2
  56. Baig K, Price MO, Price FW. Descemet’s stripping with endothelial keratoplasty. US Ophthalmic Review 2007; 34-36.
  57. Price FW. “Small bubble technique” helps “big bubble technique”. British Journal of Ophthalmology, 2007; 91:1260-1.
  58. Allan B, Terry MA, Price FW, Price MO, Griffin N, Claesson M. Corneal transplant rejection rate and severity after endothelial keratoplasty. Cornea 2007; 26:1039-42.
  59. Price FW. Re: central toxic keratopathy: description of a syndrome in laser refractive surgery. American Journal of Ophthalmology, 2007; 144:331-2.
  60. Price MO, Price FW. Descemet’s stripping endothelial keratoplasty. Current Opinion in Ophthalmology 2007; 18:290-4.
  61. Price MO, Price FW. Descemet stripping with endothelial keratoplasty for treatment of iridocorneal endothelial syndrome. Cornea 2007;26:493-497.
  62. Hainline BC, Choi DM, Price MO, Price FW. Central flap necrosis after LASIK with microkeratome and femtosecond laser created flaps. Journal of Refractive Surgery,2007;23:233-242.
  63. Price MO, Price FW, Trespalacios R. Endothelial keratoplasty technique for aniridic aphakic eyes. J Cataract and Refract Surg 2007; 33:376-379.
  64. Lord RK, Price FW, Price MO, Werner L, Mamalis N. Histology of posterior lamellar keratoplasty. Cornea 2006;25:1093-1096.
  65. Price FW, Price MO. A nonsurgical treatment for donor dislocation after descemet stripping endothelial keratoplasty (DSEK). Cornea 2006;25:991.
  66. Romaniv N, Price MO, Price FW, Mamalis N. Donor descemet membrane detachment after endothelial keratoplasty. Cornea 2006;25:943-947.
  67. Price FW, Price MO. Endothelial keratoplasty to restore clarity to a failed penetrating graft. Cornea, 2006;25:895-899.
  68. Price MO, Price FW. Descemet’s stripping with endothelial keratoplasty: comparative outcomes with microkeratome-dissected and manually dissected donor tissue. Ophthalmology, 2006; 113:1936-1942.
  69. Price MO, Price FW. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology 2006;113:1785-90.
  70. Price FW, Price MO. Descemet’s stripping with endothelial keratoplasty in 200 eyes: Early challenges and techniques to enhance donor adherence. Journal of Cataract & Refractive Surgery, 2006;32:411-418.
  71. Price MO, Price FW, Maclellan D. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. J Cataract Refract Surg, 2005;31:2137-2141
  72. Price FW, Price MO. Descemet’s stripping with endothelial keratoplasty in 50 eyes: a refractive neutral corneal transplant. J Refractive Surg, 2005; 21:339-345.
  73. Price MO, Price FW, Werner L, Berlie C, Mamalis N. Late dislocation of scleral-sutured posterior chamber intraocular lenses. J Cataract Refract Surg, 2005,31:1321-1326.
  74. Price MO, Quillin C, Price FW. Effect of gatifloxacin ophthalmic solution 0.3% on human corneal endothelial cell density and aqueous humor gatifloxacin concentration. Current Eye Research, 2005; 30:563-567.
  75. Price FW. Corneal transplantation as a refractive surgical procedure. Journal of Refractive Surgery, 2005;21:216-217.
  76. Price FW. Pressure-induced interface keratitis: a late complication following LASIK. Cornea 2005;4:505; author reply 505.
  77. Price FW. Fixed dilated pupil (Urrets-Zavalia syndrome) in corneal dystrophies. Cornea. 2005;4:363; author reply 363.
  78. Price, FW, Mackool RJ, Miller KM, Koch P, Oetting TA, Johnson T. Interim results of the United States investigational device study of the Ophtec capsular tension ring. Ophthalmology, 2005;112:460-465.
  79. Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Current Medical Research and Opinion,2004;20:2015-2019.
  80. Price MO, Price FW, Chang DF, Kelley KA, Olson MD, Miller KM. Ophtec iris reconstruction lens United States clinical trial phase I. Ophthalmology, 2004;111:1847-52.
  81. Riddle HK, Price MO, Price FW. Topical anesthesia for penetrating keratoplasty. Cornea, 2004;23:712-714.
  82. Bowers PJ, Zeldes SS, Price FW, McManis CL, Price MO. Outcomes of laser in situ keratomileusis in a Refractive Surgery fellowship program. J Refractive Surgery, 2004;20:265-9.
  83. Price MO, Price FW. Cataract progression and treatment following posterior lamellar keratoplasty. J Cataract and Refract Surg, 2004;30:1310-5.
  84. Steinemann TL, Pinninti U, Szczotka LB, Eiferman RA, Price FW. Ocular complications associated with the use of cosmetic contact lenses from unlicensed vendors. Eye Contact Lens. 2003 Oct;29(4):196-200.
  85. Thompson RW, Choi DM, Price MO, Price FW. Noncontact optical coherence tomography for measurement of corneal flap and residual stromal bed thickness after laser in situ keratomileusis. J Refractive Surgery, 2003, 19:507-515.
  86. Price MO, Thompson RW, Price FW. Risk factors for various causes of failure in initial corneal grafts. Archives of Ophthalmology, 2003;121:1087-1092.
  87. Bowers P, Price MO, Zeldes S, Price FW. Superficial keratectomy with mitomycin-C for the treatment of Salzmann’s nodules. J Cataract and Refract Surg, 2003; 29(7):1302-6.
  88. Thompson RW, Price MO, Bowers PJ, Price FW. Long-term graft survival after penetrating keratoplasty. Ophthalmology, 2003; 110(7):1396-1402.
  89. Parker DS, Price FW. Suture fixation of a posterior chamber intraocular lens in anticoagulated patients. J Cataract Refract Surg, 2003; 29:949-954.
  90. Price FW, Dobbins K, Zeh WG. Penetration of topically administered ofloxacin and trimethoprim into aqueous humor. J Ocul Pharmacol Ther, 2002; 18:445-53.
  91. Thompson RW, Choi DM, Price FW. Clear lens replacement surgery. International Ophthalmology Clinics, 2002; 42: 131-152.
  92. Price FW. Corneal endothelial damage after trabeculectomy with mitomycin C in two patients with glaucoma with cornea guttata. 2002 Oct;21(7):733.
  93. Choi DM, Thompson RW, Price FW. Incisional refractive surgery. Current Opinion in Ophthalmology 2002; 13:237-241.
  94. Price FW. Topical corticosteroids after keratorefractive surgery. J Cataract Refract Surg. 2002 Aug;28(8):1307; author reply 1307-8.
  95. Price, FW, Ziemba, SL. Placement of a collagen glaucoma drainage device to control intraocular pressure and chronic iritis secondary to juvenile rheumatoid arthritis. Ophthalmic Surgery and Lasers, 2002;3:233-36.
  96. Price FW, Price MO, Zeh WG, Dobbins K. Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double-masked, placebo-controlled trial. J Refract Surg, 2002 Mar-Apr; 18(2):140-4.
  97. Price FW, Willes L, Ries J, Lyng A, Price M. A prospective, randomized comparison of the use versus non-use of topical corticosteroids after laser in situ keratomileusis. Ophthalmology, 2001 Jul; 108(7):1236-44;discussion 1244-5.
  98. Price FW, Zeh WG. Viscoelastic material as an adjunct to dissections and to treat microperforations during nonpenetrating filtering surgery. J Cataract Refract Surg, 2001 Apr; 27(4):639-641.
  99. Dobbins K, Price FW, Whitson WE. Trends in the indications for penetrating keratoplasty in the midwestern United States. Cornea 2000 Nov;19(6):813-816.
  100. Price FW. New pieces for the puzzle: nonsteroidal anti-inflammatory drugs and corneal ulcers. J Cataract Refract Surg. 2000 Sep;26:1263-65.
  101. Zeh WG, Price FW. Iris fixation of posterior chamber intraocular lenses. J Cataract Refract Surg, 2000 Jul;26(7):1028-34.
  102. Price FW, Koller DL, Price MO. Cent Central corneal pachymetry in patients undergoing laser in situ keratomileusis. Ophthalmology 1999 Nov;106(11):2216-2220.
  103. Riddle HK, Parker DAS, Price FW. Management of postkeratoplasty astigmatism. Current Opinion in Ophthalmology 1998 Aug;9(IV):15-28.
  104. Price FW Jr., Belin MW, Nordan LT, McDonnell PJ, Pop M. Epithelial haze, punctate keratopathy, and induced hyperopia after photorefractive keratectomy for myopia. J Refract Surg. 1999 May-June;15(3):384-7.
  105. Faktorovich EG, Maloney RK, Price FW, ARC-T Study Group. Effect of astigmatic keratotomy on spherical equivalent: results of the Astigmatism Reduction Clinical Trial. Am J Ophthalmol. 1999;127:260-9.
  106. Loden JC, Price FW Jr. Price graft-over-host technique to manage positive pressure during penetrating keratoplasty. J Cataract Refract Surg. 1998;24:736-8.
  107. Price FW, Parker DA. Horizontal corneal diameter and its implications for implanting sulcus-fixated lenses. J Cataract Refract Surg. 1997 Oct;23(8):1131-2.
  108. Price FW, Whitson WE, Gonzales JS, Johns SK. Corneal tissue levels of topically applied ofloxacin. J Cataract Refract Surg 1997;23:898-902
  109. Price FW, Green RB, Marks RG, Gonzales J. Arcuate transverse keratotomy for astigmatism followed by subsequent radial or transverse keratotomy. ARC-T Study Group. Astigmatism Reduction Clinical Trial. J Refract Surg 1996;12:68-76.
  110. Price FW. Central islands of corneal steepening after automated lamellar keratoplasty for myopia. J Refract Surg 1996;12:36-41.
  111. Price FW, Whitson WE, Gonzales JS, Gonzales CR, Smith J. Automated lamellar keratomileusis in situ for myopia. J Refract Surg 1996;12:29-35.
  112. Price FW, Whitson WE, Johns SK, Gonzales JS. Risk factors for corneal graft failure. J Refract Surg 1996;12:133-146.
  113. Steinert RF, Storie B, Smith P, McDonald MB, van Rij G, Bores LD, Colin JP, Durrie DS, Kelley C, Price FW, Rostron C, Waring III GO, Nordan LT. Hydrogel intracorneal lenses in aphakic eyes Arch Ophthalmol 1996:114:135-141.
  114. Price FW, Hanna SI. Bilateral penetrating autokeratoplasty. J Refract Surg 1995;11: 494-496.
  115. Price FW, Wellemeyer ML. Transscleral fixation of posterior chamber intraocular lenses. J Cataract Refract Surg 1995;20:567-573.
  116. Price FW, Green RB, Marks RG, Gonzalas JS. Astigmatism reduction clinical trial: a multicenter prospective evaluation of the predictability of arcuate keratotomy. Evaluation of surgical nomogram predictability. ARC-T Study Group. Arch Ophthalmol 1995;113:277-282.
  117. Price FW, Whitson WE, Collins KS, Gonzales JS. Corneal tissue levels of topically applied ciprofloxacin. Cornea 14(2);152-156,1995.
  118. Price FW, Wellemeyer ML. Long-term results of Molteno implants. Ophthalmic Surg 1995;26(2):1-6.
  119. Price FW, Whitson WE, Ahad KA, Tavakkoli H. Suprachoroidal hemorrhage in penetrating keratoplasty. Ophthalmic Surg 1994;25(8):521-525.
  120. Lee DA, Price FW, Whitson, WE. Intraocular complications associated with the Dubroff anterior chamber lens. J Cataract Refract Surg 1994;20:421-425.
  121. Whitcup SM, Nussenblatt RB, Price FW, Chan CC. Expression of cell adhesion molecules in corneal graft failure. Cornea 1993;12(6):475-480.
  122. Price FW, Whitson WE, Collins KS. Five-year corneal graft survival. A large, single-center patient cohort. Arch Ophthalmol 1993;111:799-805.
  123. Wellemeyer ML, Price FW. Molteno implants in patients with previous cyclocryotherapy. Ophthalmic Surg 1993;24:395-398.
  124. Coli AF, Price FW, Whitson WE. Intraocular lens exchange for anterior chamber intraocular lens-induced corneal endothelial damage. Ophthalmology 1993;100:384-393.
  125. Lee DA, Price FW. Management of concurrent corneal diseases and cataract. Cur Opin Ophthalmol 1993,4;1:97-101.
  126. Price FW, Whitson WE, Collins KS, Johns SK. Explantation of posterior chamber lenses. J Cataract Refract Surg 1992;18:475-479.
  127. Price FW, Whitson WE, Collins KS, Johns SK. Changing trends in explanted intraocular lenses: a single center study. J Cataract Refract Surg 1992;18:470-474.
  128. Whitson WE, Price FW. Reducing hypotony after Molteno procedure. Ophthalmic Surg 1992;23(6):434.
  129. Price FW. Penetrating keratoplasty for keratoconus. Bri J Ophthalmol 1992;6(1):61.
  130. Price FW, Whitson WE. Progression of visual acuity after penetrating keratoplasty. Ophthalmology 1991;98:1177‑1185.
  131. Lopez JS, Price FW, Whitcup SM, Li Q, de Smet M, Chan CC. Immunohistochemistry of Terrien’s and Mooren’s corneal degeneration. Arch Ophthalmol 1991;109:988‑992.
  132. Price FW, Whitson WE. Graft survival in four common groups of patients undergoing penetrating keratoplasty. Ophthalmology 1991;98:322‑328.
  133. Price FW, Whitson WE. The art of surgical correction for postkeratoplasty astigmatism. Int Ophthalmol Clin. 1991;31:59-67.
  134. Price FW, Whitson WE. Polypropylene ligatures with Molteno implants. Ophthalmic Surg. 1990 Aug;21(8):597.
  135. Mamalis N, Craig MT, Price FW. Spectrum of Nd:YAG laser-induced intraocular lens damage in explanted lenses. J Cataract Refract Surg 1990;16:495‑500.
  136. Price FW, Whitson WE. Suprachoroidal hemorrhage after placement of a scleral-fixated lens. J Cataract Refract Surg 1990;16(4):514‑515.
  137. Price FW, Whitson WE. Natural history of cystoid macular edema in pseudophakic bullous keratopathy. J Cataract Refract Surg 1990;16(2):163‑169.
  138. Price FW, Whitson WE. Polypropylene ligatures as a means of controlling intraocular pressure with Molteno implants. Ophthalmic Surgery 1989;20:781‑783.
  139. Apple DJ, Price FW, Gwin RT, Imkamp E, Daun M, Casanova R, Hansen S, Carlson AN. Sutured retropupillary posterior chamber intraocular lenses for exchange or secondary implantation. The 12th annual Binkhorst lecture, 1988. Ophthalmology 1989;96:1241‑1247.
  140. Price, FW, Whitson, WE: Visual results of suture-fixated posterior chamber lenses during penetrating keratoplasty. Ophthalmology 96;8:1234‑1240, 1989.
  141. Price FW. Air lamellar keratoplasty. Refract and Corneal Surg 1989;5:240‑243.
  142. Price, FW: A controlled method of removing the Stableflex lens. J Cataract Refract Surg 14:81‑83,1988.
  143. Price FW. Factors contributing to corneal decompensation with the Stableflex lens. J Cataract Refract Surg 14:53‑57,1988.
  144. Price FW, Binder PS. Scarring of a recipient cornea following epikeratoplasty. Arch Ophthalmol 1987;105:1556‑1560.
  145. Tetz MR, Apple DJ, Price FW, Piest KL, Kincaid MC, Bath, PE. A newly described complication of neodymium-YAG laser capsulotomy: exacerbation of an intraocular infection. Case report. Arch Ophthalmol 1987;105:1324‑1325.
  146. Piest KL, Kincaid MC, Tetz MR, Apple DJ, Roberts WA, Price FW. Localized endophthalmitis: a newly described cause of the so-called toxic lens syndrome. J Cataract Refract Surg 1987;13:498‑510.
  147. Price FW, Schlaegel TF. Bilateral acute retinal necrosis. Am J Ophthalmol 1980;89:419‑424.
  1. A multicenter clinical evaluation of the EVO/EVO+ Visian® Implantable Collamer® Lens. Staar Surgical, 2020/Active.
  2. Post-approval study of the Visian® Toric Implantable Collamer® Lens. Staar Surgical, 2020/Active.
  3. Prospective randomized study to determine whether use of Rhopressa™ can ammeliorate corneal edema associated with Fuchs dystrophy. Cornea Research Foundation of America, 2019/Active.
  4. Effect of Xen implantation on the aqueous humor proteome. Cornea Research Foundation of America, 2019/Active.
  5. Prospective randomized study to determine whether use of Rhopressa™ accelerates corneal clearing after removal of Descemet membrane for treatment of Fuchs dystrophy, Cornea Research Foundation of America/Price Vision Group, 2019/Active
  6. Randomized Comparison of Standard vs Accelerated Corneal Cross Linking for Treatment of Progressive Keratoconus or Ectasia, Cornea Research Foundation of America/Price Vision Group, 2019/Active
  7. A randomized, double-masked, placebo-controlled study of the safety of Amphotericin 0.255 μg/mL in Optisol-GS, Price Vision Group/Cornea Research Foundation of America, 2019/2019
  8. Sub-Investigator. A multi-center, double-masked, randomized, placebo-controlled study of the efficacy and safety of HY02 ointment in subjects with inflamed Meibomian gland dysfunction. Hovione Scientia, 2019/Active.
  9. Principal Investigator.A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants with Presbyopia, Allergan, 2019/Active.
  10. Co-Investigator.Phase 3, double-masked, randomized, controlled study of KPI-121 0.25% Ophthalmic suspension compared to vehicle in subjects with dry eye disease (Stride 3), Kala, 2018/Active
  11. Principal Investigator. Effect of TrueTear use on anterior corneal surface imaging quality. Price Vision Group. 2018/2019.
  12. Principal Investigator. Comparison of the aqueous humor in eyes undergoing routine cataract surgery vs. eyes having a transplant to treat Fuchs dystrophy vs. eyes having a regraft for cornea transplant failure. Cornea Research Foundation of America. 2018/Active.
  13. Co-Investigator. Genetic susceptibility to contact lens related microbial keratitis. University Hospitals Cleveland Medical Center, 2018/Active.
  14. Principal Investigator. Evaluation of keratoplasty outcomes. Cornea Research Foundation of America 2018/Active.
  15. Principal Investigator. Retrospective study of treatments for keratoconus or ectasia. Cornea Research Foundation of America. 2017/Active.
  16. Investigator, Artisan Aphakia Lens for the Correction of Aphakic in Adults, Ophtec, USA, 2017/Active
  17. Co-Investigator. Discovery approach to ocular hypertension. National Institutes of Health, 2017/Active.
  18. Principal Investigator. Randomized, double-masked, placebo-controlled evaluation of netarsudil for prevention of corticosteroid-induced intraocular pressure elevation. Cornea Research Foundation of America 2017/2019.
  19. Sub-Investigator. A double-masked, randomized, multi-center Phase 2 study to evaluate the efficacy and safety of LacripepTM in subjects with dry eye associated with primary Sjogren’s syndrome. TearSolutions, Inc. 2017/2018.
  20. Principal Investigator. Survey after crosslinking. Cornea Research Foundation of America 2017.
  21. Principal Investigator, Evaluation of a camera attachment on a surgical microscope for cataract, anterior segment, cornea, and glaucoma surgery. Haag-Streit 2016/Active.
  22. Principal Investigator, Characterization of the aqueous humor proteome before and after micropulse laser treatment for intraocular pressure reduction. Cornea Research Foundation of America 2016/2017.
  23. Principal Investigator, A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the Concurrent Use of AGN-190584 and AGN-199201 in Patients with Presbyopia. Allergan 2016/2018.
  24. Sub-Investigator, A Phase 3, double-masked, randomized, controlled study of KPI-121 0.25% ophthalmic suspension compared to vehicle in subjects with dry eye disease. Kala Pharmaceuticals 2016/2018.
  25. Principal Investigator, A multi-center, open-label, parallel-arm, randomized, dose-ranging study of ENV515 (travoprost) intracameral implant in subjects with bilateral ocular hypertension or early primary open-angle glaucoma. Envisia Therapeutics Inc. 2015.
  26. Principal Investigator, Color vision before and after Descemet membrane endothelial keratoplasty (DMEK) compared with age-matched controls. Cornea Research Foundation of America 2015/2016.
  27. Principal Investigator, A Phase III double-masked, randomized, controlled trial of KPI-121 in postsurgical inflammation. Kala Pharmaceuticals, Inc. 2014/2015.
  28. Principal Investigator. Randomized comparison of the use vs. non-use of mitomycin C in combination with epithelial removal and Descemet membrane endothelial keratoplasty. Cornea Research Foundation of America 2014/2015.
  29. Principal Investigator, Safety and effectiveness of the CustomFlex artificial iris prosthesis for the treatment of iris defects. Clinical Research Consultants, Inc. 2013/2018.
  30. Sub-investigator, A historically-controlled Phase II/III study to evaluate efficacy and safety of Kedrion human plasminogen eye drop preparation in patients diagnosed with ligneous conjunctivitis. Kedrion 2013/Active.
  31. Principal Investigator A multi-center, randomized, placebo-controlled evaluation of the safety and efficacy of the KXL system with VibeX (riboflavin ophthalmic solution) for corneal collagen cross-linking in eyes with keratoconus. Protocol KXL-005. Avedro 2013/2017.
  32. Principal Investigator, Evaluation of a camera attachment on a surgical microscope for cataract, anterior segment, cornea, and glaucoma surgery. Haag-Streit 2013/2015.
  33. Principal Investigator. Prospective, randomized comparison of corticosteroid dosing regimens following endothelial keratoplasty. Cornea Research Foundation of America 2013/2015.
  34. Principal Investigator. Kaneka TrimotionTM Injector Clinical Trial. Kaneka 2013.
  35. Principal Investigator. Prospective study of the incidence of graft rejection episodes and intraocular pressure elevation in the second year after Descemet membrane endothelial keratoplasty. Cornea Research Foundation of America 2012/2016.
  36. Principal Investigator. A multi-center, randomized, placebo-controlled evaluation of the safety and efficacy of the KXL system with VibeX (riboflavin ophthalmic solution) for corneal collagen cross-linking in eyes with keratoconus. Protocol KXL-002. Avedro 2012/2017.
  37. Principal Investigator. A prospective, double-masked, placebo controlled comparison of topical 0.15% ganciclovir gel (Zirgan) versus 0.3% hypromellose gel (Genteal gel; placebo) for the treatment of adenovirus conjunctivitis. Lifelong Vision Foundation 2011/2013.
  38. Principal Investigator. Evaluation of the Epiglare tester for the measurement of glare-induced changes in best spectacle corrected visual acuity in subjects with and without cataracts. Epico LLC 2011/2012.
  39. Principal Investigator. Comparison of two corticosteroid-dosing regimens for prevention of corneal transplant rejection episodes after Descemet’s membrane endothelial keratoplasty. Cornea Research Foundation of America 2011/2013.
  40. Principal Investigator. Characterization of the protein content of aqueous humor as related to cornea transplant survival. Cornea Research Foundation of America 2011/2015.
  41. Principal Investigator. A Comparison of Three Endothelial Microscopy Techniques. Cornea Research Foundation of America 2011.
  42. Principal Investigator. Efficacy and Safety of Bromfenac Ophthalmic Solution vs. Placebo for The Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery. ISTA 2011.
  43. Principal Investigator. A randomized, prospective, double masked clinical trial of Life 4°C vs. Optisol GS corneal storage media. Numedis, Inc. 2011/2012.
  44. Principal Investigator. Survey study comparing contact lenses and LASIK for vision correction. Cornea Research Foundation of America 2010/2016.
  45. Principal Investigator. A multi-center, double-masked, randomized, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of 0.005% and 0.010% aqueous cyclosporine ophthalmic solutions administered twice daily for at least two weeks prior to and six months after LASIK surgery in reducing post-LASIK corneal hypoesthesia. Allergan 2010/2011.
  46. Principal Investigator. Evaluation of Corneal Cross Linking for Treatment of Corneal Edema. Cornea Research Foundation of America. 2010/2011.
  47. Principal Investigator. Evaluation of two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes with Progressive Keratoconus or Ectasia. Cornea Research Foundation of America 2010/2017.
  48. Principal Investigator. Clinical Protocol for the Treatment of Corticosteroid Induced Intra-ocular Pressure Increases After Corneal Transplantation. Cornea Research Foundation of America 2009/2010.
  49. Principal Investigator. A Prospective Evaluation of Treatment Duration of the UVXTM System for treating infectious keratitis. Cornea Research Foundation of America 2009/2013.
  50. Principal Investigator A prospective multi-center clinical study to evaluate the safety and effectiveness of the light adjustable lens (LAL) in subjects undergoing cataract extraction. Calhoun Vision, Inc. 2009/2013.
  51. Principal Investigator A Multi-Center, Parallel-Group, Double-Masked, Randomized, Placebo-Controlled Study of the Effects of diquafosol tetrasodium Ophthalmic Solution, 2% in Subjects with Dry Eye Disease and a Central Corneal Staining Score of 3 (NEI Scale). Inspire Pharmaceuticals, Inc. 2009/2010.
  52. Principal Investigator Efficacy and safety of bromfenac ophthalmic solution QD vs. placebo QD for treatment of ocular inflammation and pain associated with cataract surgery. ISTA Pharmaceuticals, Inc. 2009.
  53. Principal Investigator A prospective study of Staar ICL metrics. Cornea Research Foundation of America – 2008/2009.
  54. Principal Investigator. A randomized, observer-masked, parallel-group, multicenter trial evaluating the ocular penetration of 1.5% levofloxacin ophthalmic solution and 0.5% moxifloxacin ophthalmic solution in subjects undergoing corneal transplant surgery. Vistakon Pharmaceuticals, LLC – 2008/2009.
  55. Principal Investigator. Open-enrollment, prospective study of endothelial keratoplasty outcomes. Cornea Research Foundation of America – 2008/Active.
  56. Principal Investigator. Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Progressive Keratoconus. Peschke Meditrade GmbH – 2008/2011.
  57. Principal Investigator Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Corneal Ectasia after Refractive Surgery. Peschke Meditrade GmbH – 2008/2011.
  58. Principal Investigator Characterization of the protein content of aqueous humor. Cornea Research Foundation of America 2008/2013.
  59. Principal Investigator Surveillance of resistance to formulations of antimicrobials in cultures of the eye. Allergan, Inc. 2007/2008.
  60. Principal Investigator A Multi Center, Double Masked, Randomized Parallel Group Study Evaluating the Safety and Efficacy of a New Formulation of Ketorolac Tromethamine 0.45% Ophthalmic Solution Compared with Vehicle Administered Preoperatively and Twice-Daily Postoperatively for Two Weeks for the Treatment of Anterior Segment Inflammation, Pain, and Inhibition of Surgically Induced Miosis Following Cataract Extraction with Posterior Chamber Intraocular Lens (IOL) Implantation. Allergan, Inc. 2007/2008.
  61. Principal Investigator A prospective, randomized, multicenter center study evaluating the use of intraocular dexamethasone in conjunction with Descemet’s stripping and endothelial keratoplasty, a type of cornea transplant. Cornea Research Foundation of America and Ophthalmic Consultants of Long Island – 2007/2009.
  62. Principal Investigator Intraocular Pressure after Descemet’s stripping endothelial keratoplasty as measured by contour matching tonometry and applanation tonometry. Cornea Research Foundation of America – 2007.
  63. Principal Investigator. Clinical evaluation of the safety and effectiveness of the Veriflex anterior chamber phakic IOL for the correction of myopia. Advanced Medical Optics – 2007/2016.
  64. Principal Investigator. A multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study to assess the efficacy and safety of LX201 implantation for the prevention of corneal allograft rejection episodes or graft failure in subjects who have experienced one or more rejection episodes following penetrating keratoplasty. Lux Biosciences – 2007/2010.
  65. Principal Investigator. A multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study to assess the efficacy and safety of LX201 for the prevention of allograft rejection episodes and graft failure following penetrating keratoplasty with LX201 implantation in subjects who are at increased immunological risk. Lux Biosciences – 2007/2010.
  66. Principal Investigator. A prospective, multi-center feasibility trial to evaluate the safety and effectiveness of the IntraLase FS laser used to harvest donor tissue for Descemet’s stripping with endothelial keratoplasty. IntraLase Corp. – 2007/2008.
  67. Principal Investigator. A Randomized Evaluation of Two Surgical Kits: Gatifloxacin, Ketorolac LS, and Pred Forte Compared with Moxifloxacin, Nepafenac, and EconoPred in Patients Undergoing Cataract Surgery. William Trattler, MD – 2006.
  68. Principal Investigator. Comparative Study of Corneal Transplant Survival and Endothelial Cell Loss following Descemet Stripping Automated Endothelial Keratoplasty vs. Penetrating Keratoplasty. Case Vision Research Coordinating Center – 2006/2010.
  69. Principal Investigator. FECD Genetics Multi-Center Study. Case Vision Research Coordinating Center – 2006/2010.
  70. Principal Investigator. A prospective, randomized, single center study evaluating use of surgeon- and eye bank-prepared donor tissue for Descemet’s stripping and endothelial keratoplasty, a type of cornea transplant. Protocol 2005-10. Cornea Research Foundation of America and the North Carolina Eye Bank, Inc. – 2006/2007.
  71. Principal Investigator. A prospective, multi-center feasibility trial to evaluate the IntraLase FS laser used for penetrating keratoplasty. Protocol FMTO-007-ITK.  IntraLase Corp. – 2005/2006.
  72. Principal Investigator Randomized, controlled, multicenter comparative trial to evaluate the SOLX Gold Shunt for the reduction of intraocular pressure (IOP) in glaucomatous eyes following failed medical and conventional surgical treatments. Protocol SLX53.  SOLX – 2005/2013.
  73. Principal Investigator. A masked comparison of Acular LS plus steroid versus steroid alone for the prevention of macular leakage in cataract patients. John Wittpenn, MD – 2005/2007.
  74. Principal Investigator. Comparison of healing response of the corneal wound created by blade or femtosecond laser, in presence of implanted hydrogel sponge. Protocol 2902. CooperVision – 2005.
  75. Principal Investigator. A multi-center, double-masked, randomized, placebo controlled, evaluation of the onset and duration of action of R89674 0.25% ophthalmic solution in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis. Protocol 05-003-11.  Vistakon Pharmaceuticals, LLC – 2005/2006.
  76. Principal Investigator. A study to determine whether early corneal protein changes associated with keratoconus can be identified through 2-dimensional gel electrophoresis and mass spectrometric analysis of human tear samples. Protocol: K-10-03-001.  Cornea Research Foundation of America – 2004/2006.
  77. Principal Investigator. A prospective, randomized, single-center clinical trial to evaluate the use of orbital seal sunglasses after LASIK. Protocol 2004-20.  Panoptx – 2004/2005.
  78. Principal Investigator. A prospective, randomized, multi-center clinical comparison of fellow eyes undergoing LASIK with either a mechanical keratome or IntraLase FS laser. Protocol PRIM-016-CST.  IntraLase Corp – 2004/2005.
  79. Principal Investigator. A prospective, single-center feasibility trial to evaluate the safety and effectiveness of the IntraLase FS laser used for corneal endostromal tissue harvesting. Protocol FMTO-006-ITK.  IntraLase Corp – 2004/2005.
  80. Principal Investigator. Clinical study of implantation of a UV-absorbing acrylic posterior chamber intraocular lens. Protocol 2003-A101.  Hoya Holdings, Inc. – 2004/2008.
  81. Principal Investigator. A study to determine if RestasisTM (cyclosporin 0.05% ophthalmic solution) is effective, either alone or in combination with pulsed dosing of corticosteroids, for prevention of graft rejection episodes after corneal transplantation. Protocol R-09-03-002.  Price Vision Group – 2003/2005.
  82. Principal Investigator. A prospective, randomized, double-masked study to evaluate whether pre-operative dosing with Acular LS is effective for maintaining pupil dilation and for mitigating pain and inflammation during and after cataract surgery. Protocol A-09-03-001.  Price Vision Group – 2003/2004.
  83. Principal Investigator. A Study to Compare the Effect of Gatifloxacin 0.3% and Moxifloxacin 0.5% Ophthalmic Solutions on Corneal Epithelial cell health following two dosing regimens. Protocol 08-03-001.  Price Vision Group – 2003.
  84. Principal Investigator. A comparison of the duration of IOP control with travopost, bimatoprost, and latanoprost in patients with glaucoma and ocular hypertension: a multicenter, randomized, masked-evaluator, parallel group study. Protocol 03-005-03.  Ophthalmic Research Associates – 2003.
  85. Principal Investigator. To evaluate the effect of gatifloxacin 0.3% ophthalmic solution on corneal endothelial cell counts in two subpopulations: non-surgical, normal healthy volunteers and healthy volunteers scheduled to undergo standard cataract surgery.  Protocol PIND-GATI-004.  Allergan – 2003.
  86. Principal Investigator. A comparative study of olopatadine QD versus vehicle in patients with seasonal allergic conjunctivitis or rhinoconjunctivitis. Protocol C-02-67.  Alcon – 2003.
  87. Principal Investigator. Phase II study: a multi-center, double-masked, randomized, vehicle-controlled, parallel group study to evaluate the safety and efficacy of testosterone (0.01%, 0.03% and 0.1%) ophthalmic solution administered twice daily for up to 6 months in patients with Meibomian gland dysfunction (MGD). Allergan 2003/2003.
  88. Medical Monitor and Principal Investigator. Multicenter Clinical Study of the Ophthec Model 311 Iris Reconstruction Lens. FDA IDE Number: G020127 and G020127/A001.  OPHTEC USA, Inc. – 2002/
  89. Principal Investigator. Multicenter Clinical Study of the OCULAID Endocapsular Tension Ring (CTR) and OPERAID Tension Ring Inserter. FDA IDE Number: G010064.  Protocol CTR 275/276. OPHTEC USA, Inc.– 2001/2004
  90. Principal Investigator. A multi-center, randomized, double-masked, vehicle-controlled, parallel-group study evaluating the safety and analgesic efficacy of Ketorolac Tromethamine 0.4% ophthalmic solution in post photorefractive keratectomy patients. Protocol 191578-003. Allergan – 2001/2002
  91. Principal Investigator. A prospective, masked study comparing preservative-free Acular to vehicle for analgesic efficacy after LASIK. Allergan – 2000/2001.
  92. Principal Investigator – A prospective, masked study to compare the effectiveness of antibiotics to penetrate into the eye. Allergan – 2000/2001.
  93. Principal Investigator. The Cornea Donor Study: A prospective cohort study to determine whether the graft-failure rate over a 5-year follow-up period is equivalent with corneal tissue from donors older than 65 years of age compared with that from younger donors. Two other specific objectives also evaluated.  Protocol Version 1.0- Jaeb Center for Health Research – 1999/2012.
  94. Co-Investigator. Clinical evaluation of a new method to remove the Landec Punctal Occluder. Protocol C-98-15. Alcon Laboratories, Inc. – 1999
  95. Principal Investigator. US Clinical Study of the Artisan Myopia Lens for the Correction of High Myopia in Phakic Eyes. Ophtec USA, Inc. – 1998/2007
  96. Principal Investigator and Sponsor. A Phase III Prospective Controlled Clinical Trial to Investigate the Ability to Decrease the Rate of Over-correction without Increasing the Rate of Retreatment due to Under-correction with Laser in Situ Keratomileusis. EXKM-802.   Protocol 980968. Corneal Consultants of Indiana – 1998-9/2000
  97. Principal Investigator. Clinical study of the implantable contact lens for patients with moderate to high hyperopia. Protocol 980363. STAAR® Surgical – 1998-4/2000
  98. Principal Investigator. A Phase III study of MDX-RA compared with placebo administered in
  99. patients undergoing phacoemulsification or planned extracapsular extraction for cataract. Protocol CL-SEC014.  – Medarex, Inc. 1998-4/2000
  100. Principal Investigator. A Multi-Center Prospective Clinical Study to Evaluate the Use of the LADARVision Excimer Laser System in LASIK Correction of Hyperopia and Astigmatism. Protocol 7201-0022. Autonomous Technologies Corporation – 1998/2000
  101. Principal Investigator. A Multi-Center Prospective Clinical Study to Evaluate the Use of LADARVision System in Correction of Hyperopia and Astigmatism. Protocol 7201-0010. Autonomous Technologies Corporation – 1998/1999
  102. Principal Investigator and Sponsor. A Phase III prospective randomized controlled clinical trial to investigate the use versus non-use of topical corticosteroids on the stability of the manifest refraction after the surgical correction of myopia and astigmatism with laser in situ keratomileusis. Protocol EXKM-801. Corneal Consultants of Indiana – 1997/2000
  103. Principal Investigator and Sponsor. A Phase III prospective randomized controlled clinical trial to investigate the simultaneous versus sequential surgical correction of myopia and astigmatism with laser in situ keratomileusis. Protocol EXKM-800. Corneal Consultants of Indiana – 1996
  104. Co-Investigator for a Phase III prospective multi center clinical trial to evaluate the safety of the Chiron Technolas™ Keracor™ 116 excimer laser for the correction of mild myopia and astigmatism in fellow eyes of subject initially treated under protocol EXCM-650-MYO. Protocol EXCM-651-FEL. Chiron Vision Corp. – 1995
  105. Co-Investigator for a Phase III prospective multi center clinical trial to evaluate the safety and effectiveness of the Chiron Technolas™ 116 excimer laser for the correction of mild myopia. Protocol EXCM-650-MYO. Chiron Vision Corp. – 1995
  106. Co-Investigator for a protocol for the retreatment of eyes with under-corrected refractive error following photorefractive keratectomy with the Chiron Technolas™ Keracor™ 116 excimer laser. Protocol EXCM-622-RET. Chiron Vision Corp. – 1995
  107. Co-Investigator for a clinical trial to evaluate the use of the Chiron Technolas Keracor™ 116 excimer laser for the correction of residual myopia or of untreated fellow eyes in patients treated with the Taunton 2015 excimer laser. Protocol EXCM-620-TET. Chiron Vision Corp. – 1995
  108. Principal Investigator for the analgesic efficacy of ketorolac tromethamine 0.5% diclofenac sodium 0.1% when used following bilateral radial keratotomy. Allergan Pharmaceuticals – 1995
  109. Principal Investigator for a Phase II prospective randomized controlled multi center clinical trial to compare surgical correction of myopia with excimer laser photorefractive keratectomy versus laser in situ keratomileusis. Protocol EXKM-603-MYO. Chiron Vision Corp.- 1995
  110. Principal Investigator for a Phase II multi center clinical trial to evaluate the use of the excimer laser for the treatment of superficial corneal opacities. Protocol EXCM-615-PTK. Chiron Vision Corp. – 1994
  111. Principal Investigator for a retrospective ALK study. Submitting 100 patients. Refractive Services Agency – 1994
  112. Principal Investigator for the analgesic efficacy and safety of KETOROLAC non-preserved ophthalmic solution in subjects undergoing radial keratotomy. Study KETO-105-8718 Allergan – 1994/1995
  113. Principal Investigator for a randomized open clinical trial for the evaluation of corneal tissue levels following topical dosing with OCUFLOX solution. Allergan – 1994
  114. Principal Investigator for an adjunctive therapy with Galardin™ matrix metalloproteinase inhibitor (GM 6001) in patients with corneal ulcers caused by infection. Galardin – 1993/1994
  115. Principal Investigator for a retrospective multi center clinical study to evaluate the clinical outcome of keratorefractive surgery for the correction of myopia and astigmatism. Chiron IntraOptics -1992/1993
  116. Principal Investigator for a prospective multi center clinical trial to evaluate keratorefractive surgery for the correction of myopia and astigmatism. Chiron IntraOptics – 1992/1993
  117. Principal Investigator for a prospective multi center clinical trial to evaluate keratorefractive surgery for the correction of myopia. Chiron IntraOptics – 1992/1993
  118. Principal Investigator for a randomized open clinical trial for the evaluation of corneal tissue levels following topical dosing with CILOXAN solution. Alcon Laboratories – 1992/1993
  119. Principal Investigator for clinical trials to evaluate the excimer laser used for photorefractive keratectomy (PRK), Phase III ‑ VISX Incorporated – 1992-1994
  120. Principal Investigator for clinical trials to evaluate the excimer laser for use in phototherapeutic corneal surgery (PTK), Phase IIB – VISX Incorporated – 1992-1995
  121. Principal Investigator for a randomized, double‑masked clinical trial to assess the safety and comparative efficacy of three concentrations of Sandimmune ophthalmic ointment versus placebo in patients with keratoconjunctivitis sicca. ‑ Sandoz Research Institute – 1991
  122. Principal Investigator for a clinical trial to evaluate the handling, fit, retention, and comfort of the Chiron corneal shield in postoperative patients. ‑ Chiron Ophthalmics, Inc.- 1991
  123. Principal Investigator for intraocular pressure raising potential of Rimexolone in high steroid responders. ‑ Alcon Laboratories – 1991/1992
  124. Principal Investigator for a randomized controlled multi center study to evaluate the effect of collagen shields on corneal epithelialization following pene­trating keratoplasty. Chiron Ophthalmics, Inc. – 1991
  125. Principal Investigator for clinical trials to evaluate the safety and efficacy of Sandimmune 2% Ophthalmic Ointment in the prevention of corneal graft rejection following “high risk” keratoplasty. Sandoz Research Institute, East Hanover, NJ – 1989-1992
  126. Principal Investigator for placebo‑controlled study to evaluate the safety and efficacy of Fibronectin ophthalmic solution in patients with keratoconjunctivitis sicca. Chiron Ophthalmics, Inc., Irvine, CA – 1988-1990
  127. Principal Investigator for clinical evaluation of corneal preser­vation media containing human Epidermal Growth Factor and insulin. Chiron Ophthalmics, Inc., Irvine, CA – 1988-1990
  128. Principal Investigator for the clinical evaluation of a hydrogel intracorneal implant (Kerato‑Gel) for the correction of aphakia; Allergan Medical Optics, Santa Ana, CA – 1988
  129. Principal Investigator for the clinical evaluation of a hydrogel intracorneal implant (Kerato‑Gel) for the correction of myopia; Allergan Medical Optics, Santa Ana, CA – 1988
  130. Principal Investigator for Fibronectin used in the treatment of recurrent corneal erosions; Chiron Ophthalmics, Inc., Irvine, CA 1987/1988
  131. Principal Investigator for Fibronectin used in the treatment of persistent corneal defects; Chiron Ophthalmics, Inc., Irvine, CA 1987/1988
  132. Principal Investigator for human Epidermal Growth Factor to promote healing of penetrating keratoplasties; Chiron Ophthalmics, Inc. – 1986/1987
  133. Principal Investigator for human Epidermal Growth Factor to promote healing of non‑healing corneal defects; Chiron Ophthalmics, Inc., Irvine, CA – 1986/1987
  134. Investigator for BKS‑1000 ‑ Non-Freeze Keratomileusis; American Medical Optics, Irvine, CA – 1986
Price Vision Group logo horiz white

Price Vision Group is a global leader in corneal transplant, cataract surgery, keratoconus treatment, PRK and LASIK. At our center in Indianapolis, we see patients from Indiana cities including Zionsville, Fishers, Carmel, Noblesville, Avon, and Greenwood, as well as people who travel from across the U.S. and even abroad for treatment by our renowned physicians.

Copyright 2022 Price Vision Group. All rights reserved.